NEWBRY — Newbury Pharmaceuticals AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK62.40m
- SEK50.73m
- SEK36.83m
- 35
- 37
- 17
- 16
Annual balance sheet for Newbury Pharmaceuticals AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 13.1 | 33.3 | 8.53 | 15.3 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 2.33 | 0.791 | 15.5 | 22.3 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Current Assets | 15.8 | 36.5 | 27.2 | 44 |
| Net Goodwill | ||||
| Net Intangible Assets | ||||
| Total Assets | 42.8 | 86.9 | 72.9 | 90.9 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 4.34 | 6.06 | 11.8 | 29.4 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 4.34 | 18.1 | 23.5 | 39 |
| Common Stock | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 38.5 | 68.8 | 49.4 | 51.9 |
| Total Liabilities & Shareholders' Equity | 42.8 | 86.9 | 72.9 | 90.9 |
| Total Common Shares Outstanding |